Tenaya Therapeutics (TNYA) Projected to Post Quarterly Earnings on Monday

Tenaya Therapeutics (NASDAQ:TNYA) will likely be announcing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Tenaya Therapeutics to post earnings of ($0.12) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 9, 2026 at 4:00 PM ET.

Tenaya Therapeutics Price Performance

Tenaya Therapeutics stock opened at $0.89 on Friday. The firm has a market capitalization of $145.40 million, a price-to-earnings ratio of -1.14 and a beta of 3.22. The company’s 50 day simple moving average is $0.72 and its 200 day simple moving average is $1.13. Tenaya Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $2.35.

Insider Buying and Selling at Tenaya Therapeutics

In other news, major shareholder Group Gp Lp Column III sold 4,056,573 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $0.68, for a total value of $2,758,469.64. Following the completion of the sale, the insider owned 2,348,183 shares of the company’s stock, valued at approximately $1,596,764.44. This represents a 63.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders sold 8,594,047 shares of company stock worth $5,430,207. 48.65% of the stock is owned by insiders.

Institutional Trading of Tenaya Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Scientech Research LLC acquired a new position in shares of Tenaya Therapeutics during the 3rd quarter worth about $27,000. Jefferies Financial Group Inc. acquired a new position in Tenaya Therapeutics during the third quarter worth approximately $99,000. Comerica Bank acquired a new stake in shares of Tenaya Therapeutics in the first quarter valued at approximately $50,000. Corient Private Wealth LLC bought a new position in shares of Tenaya Therapeutics during the 4th quarter worth approximately $72,000. Finally, Cetera Investment Advisers increased its holdings in shares of Tenaya Therapeutics by 107.0% during the 4th quarter. Cetera Investment Advisers now owns 106,425 shares of the company’s stock worth $76,000 after acquiring an additional 55,000 shares during the last quarter. Institutional investors and hedge funds own 90.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on TNYA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tenaya Therapeutics in a research report on Wednesday, January 21st. HC Wainwright cut their price target on shares of Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, December 12th. Canaccord Genuity Group lowered their price objective on shares of Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Chardan Capital cut their price objective on shares of Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, December 12th. Finally, Morgan Stanley set a $2.00 target price on Tenaya Therapeutics in a report on Thursday, January 8th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Tenaya Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $4.50.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.